Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7,883 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Risk Factors Associated with Durable Progression-Free Survival in Patients with Relapsed or Refractory Multiple Myeloma Treated with Anti-BCMA CAR T-cell Therapy.
Zhang M, Zhou L, Zhao H, Zhang Y, Wei G, Hong R, Wu W, Xu H, Wang L, Ni F, Cui J, Peng S, Huang CH, Chang AH, Hu Y, Huang H. Zhang M, et al. Among authors: peng s. Clin Cancer Res. 2021 Dec 1;27(23):6384-6392. doi: 10.1158/1078-0432.CCR-21-2031. Epub 2021 Sep 21. Clin Cancer Res. 2021. PMID: 34548316 Free PMC article.
Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial.
Pan J, Tan Y, Wang G, Deng B, Ling Z, Song W, Seery S, Zhang Y, Peng S, Xu J, Duan J, Wang Z, Yu X, Zheng Q, Xu X, Yuan Y, Yan F, Tian Z, Tang K, Zhang J, Chang AH, Feng X. Pan J, et al. Among authors: peng s. J Clin Oncol. 2021 Oct 20;39(30):3340-3351. doi: 10.1200/JCO.21.00389. Epub 2021 Jul 29. J Clin Oncol. 2021. PMID: 34324392 Clinical Trial.
Anti-G Protein-Coupled Receptor, Class C Group 5 Member D Chimeric Antigen Receptor T Cells in Patients With Relapsed or Refractory Multiple Myeloma: A Single-Arm, Phase Ⅱ Trial.
Xia J, Li H, Yan Z, Zhou D, Wang Y, Qi Y, Cao J, Li D, Cheng H, Sang W, Zhu F, Sun H, Chen W, Qi K, Yan D, Qiu T, Qiao J, Yao R, Liu Y, Wang X, Zhang Y, Peng S, Huang CH, Zheng J, Li Z, Chang AH, Xu K. Xia J, et al. Among authors: peng s. J Clin Oncol. 2023 May 10;41(14):2583-2593. doi: 10.1200/JCO.22.01824. Epub 2023 Mar 7. J Clin Oncol. 2023. PMID: 36881785 Free PMC article. Clinical Trial.
Anti-BCMA/GPRC5D bispecific CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, single-centre, phase 1 trial.
Zhou D, Sun Q, Xia J, Gu W, Qian J, Zhuang W, Yan Z, Cheng H, Chen W, Zhu F, Qi K, Li D, Sang W, Zhu L, Ma S, Li H, Zhang H, Qiu T, Yan D, Zhang Y, Peng S, Chang AH, Xu K, Li Z. Zhou D, et al. Among authors: peng s. Lancet Haematol. 2024 Oct;11(10):e751-e760. doi: 10.1016/S2352-3026(24)00176-5. Epub 2024 Jul 23. Lancet Haematol. 2024. PMID: 39059405 Clinical Trial.
Autologous CD7 CAR-T cells generated without T cell pre-selection in pediatric patients with relapsed/refractory T-ALL: A phase I trial.
Zhao L, Li C, Zuo S, Han Y, Deng B, Ling Z, Zhang Y, Peng S, Xu J, Duan J, Wang Z, Yu X, Zheng Q, Xu X, Yuan Y, Tian Z, Tang K, Zhang Y, Niu Q, Zhang J, Chang AH, Luo Y, Feng X, Pan J. Zhao L, et al. Among authors: peng s. Mol Ther. 2024 Sep 7:S1525-0016(24)00594-X. doi: 10.1016/j.ymthe.2024.09.006. Online ahead of print. Mol Ther. 2024. PMID: 39244642
Eosinophilic inflammation: a key player in COPD pathogenesis and progression.
Lee YL, Heriyanto DS, Yuliani FS, Laiman V, Choridah L, Lee KY, Chang JH, Chung KF, Chang LT, Chang TY, Chen XY, Peng SW, Chuang KJ, Chuang HC. Lee YL, et al. Among authors: peng sw. Ann Med. 2024 Dec;56(1):2408466. doi: 10.1080/07853890.2024.2408466. Epub 2024 Oct 7. Ann Med. 2024. PMID: 39624959 Free PMC article. Review.
7,883 results